Addictive diseases, including addiction to heroin, prescription opioids, or cocaine, pose massive personal and public health costs. Addictions are chronic relapsing diseases of the brain caused by drug-induced direct effects and persisting neuroadaptations at the epigenetic, mRNA, neuropeptide, neurotransmitter, or protein levels. These neuroadaptations, which can be specific to drug type, and their resultant behaviors are modified by various internal and external environmental factors, including stress responsivity, addict mindset, and social setting. Specific gene variants, including variants encoding pharmacological target proteins or genes mediating neuroadaptations, also modify vulnerability at particular stages of addiction. Greater understanding of these interacting factors through laboratory-based and translational studies have the potential to optimize early interventions for the therapy of chronic addictive diseases and to reduce the burden of relapse. Here, we review the molecular neurobiology and genetics of opiate addiction, including heroin and prescription opioids, and cocaine addiction.

Addiction was historically viewed as a disease of “weak personality” and was not systematically addressed by the scientific and medical communities until the latter half of the 20th century. Pioneering studies in the 1960s and 1970s led to the development of methadone, the first (and still effective and widely used) treatment for the long-term management of addictions to heroin and other opiates (1–3). During the 1980s, efforts coalesced around the investigation and development of pharmacological treatments for other drugs of abuse, including alcohol and cocaine, though there are still no approved medications for the treatment of cocaine addiction. Addictions are now commonly accepted as diseases of the brain caused by the impact of the drug itself on the brain (direct effects and neuroadaptations) and modified by various environmental factors. These factors include epigenetic changes, addict mindset, and social influences, including peer pressure, family environment, and especially, response to stress and stressors (see below). Further, the presence of specific variants of multiple genes may enhance or decrease the vulnerability to developing specific addictions. These gene variants may function synergistically with genetic polymorphisms involved in common comorbid conditions, such as anxiety or depression, and stress responsivity. Addictions can also be comorbid with major infectious disorders, such as HIV/AIDS (4).

This review focuses on current information about the molecular neurobiology and genetics of opiate addiction, including heroin and prescription opiates, and cocaine addiction, with an emphasis on the opioid receptor system (with MOP-r, KOP-r, and DOP-r receptors) and neuropeptides (β-endorphin [β-EP], dynorphins, and enkephalins) and interaction with dopaminergic systems.

**Neurobiology of addiction to MOP-r agonists or cocaine**

Heroin and prescription opioids, such as oxycodone or hydrocodone (e.g., OxyContin and Vicodin, respectively) act primarily as MOP-r agonists with relatively short duration of action, whereas cocaine (and other stimulants, e.g., methamphetamine) act primarily to increase synaptic dopamine by inhibition of dopamine reuptake or an increase in release. Activation in the dopaminergic mesocortico/mesolimbic and nigrostriatal systems, either directly in the case of cocaine or indirectly for heroin/prescription opioids or alcohol, appears to be a common neurobiological consequence of exposure to drugs of abuse (5–7).

After these initial effects of drugs on dopaminergic systems, there are short-term and long-term regulatory changes at the mRNA or protein/peptide level in major neurotransmitter and neuropeptide systems (8–12). It is hypothesized that these long-term regulatory changes, which persist even after prolonged drug-free periods, underlie the chronic relapsing nature of addictive diseases. Chronic exposure to drugs of abuse, including heroin and cocaine, induces upregulation of the KOP-r/dynorphin system. Such an endogenous activation of KOP-r tone by dynorphins is thought to underlie aversion, dysphoria/anhedonia, and depression-like or anxiety-like neuropsychiatric states. Such a counter-regulatory action by the KOP-r/dynorphin system may therefore mediate, in part, the negatively reinforcing aspects of withdrawal from drugs of abuse and may exacerbate the chronic relapsing nature of addictive diseases.

Most currently approved therapeutic agents in drug or alcohol addiction pharmacotherapy (i.e., methadone, buprenorphine, and naltrexone) are opioid receptor ligands (Figure 1). Opioid receptor mechanisms are also involved in the rewarding effects of alcohol, for which a direct pharmacodynamic target is yet to be unequivocally identified. For example, MOP-r–knockout mice exhibit less alcohol-induced reward (13). Also, one of the major medications approved for the treatment of alcoholism, naltrexone, has prominent MOP-r antagonist effects and also has affinity for KOP-r receptors (14). Stress-responsive brain areas and the hypothalamo-pituitary-adrenal (HPA) axis are also involved at particular stages of the addiction trajectory to cocaine, heroin/prescription opioids, and alcohol or recovery therefrom (15–18). The impact of these stress-related systems on addiction neurobiology will be discussed separately below.
Cocaine

The neuroanatomical localization of the immediate effects of cocaine overlap with those of the MOP-r agonists, with the nucleus accumbens (NAc) having been the most intensively studied region, as this region is thought to play an important role in the initial rewarding effects of cocaine. Other regions, including the caudate-putamen, may be involved in longer-term changes occurring in cocaine-induced addictive states. The main acute effect of cocaine is an increase in extracellular dopamine levels. Binge cocaine administration, the typical use pattern in cocaine abusers, results in successive “spikes” of dopamine concentration, as shown in animal models (19–21). Increased extracellular dopamine in dopaminergic mesocorticolimbic and nigrostriatal dopaminergic terminal fields plays a critical role in the effects of cocaine and addiction to cocaine. Dopaminergic circuitry is regulated bidirectionally by the endogenous opioid system (22); MOP-r activation results in release of dopamine (23, 24), whereas KOP-r activation is inhibitory, lowering extracellular dopamine levels (25).

We have observed increases in the levels of MOP-r in the NAc as well as in the dorsal striatum (caudate-putamen) after chronic cocaine exposure in rodent models (26). We also observed increases in KOP-r levels in the caudate-putamen and in other brain regions, including the ventral tegmental area, where the dopaminergic neurons projecting to the NAc are located (27). Changes in opioid receptor levels observed following cocaine use continue to be observed during abstinence, indicating long-term perturbations in the endogenous opioid system (28, 29). In vivo PET imaging in the brains of cocaine-addicted patients likewise shows an increase in the binding potential of MOP-r (30).

The persistent effects of cocaine on the endogenous opioid receptor/neuropeptide system, as well as the bidirectional regulation by MOP-r and KOP-r on the dopaminergic system, indicate the possibility of opioid agents as therapeutics for cocaine addiction. We have investigated this possibility in rat models, finding that methadone is effective in preventing cocaine-induced conditioned place preference (CPP, a model indicative of reward) as well as cocaine-induced neuroadaptations (31, 32). Importantly, similar findings have been observed in humans: cocaine-addicted patients in methadone or buprenorphine maintenance treatment use less cocaine (33, 34).

Naltrexone (a potent MOP-r antagonist which also has considerable affinity at KOP-r) is approved for the treatment of alcoholism and has had some effectiveness in reducing cocaine use in alcoholic patients (35). These dual-addiction diagnosis patients may provide a particular challenge, both clinically and for study design and interpretation. Of interest, naltrexone was effective in reducing use of amphetamine (another psychostimulant compound acting through the dopamine transporter) in patients without cooccurring alcoholism (36).

The KOP-r/dynorphin system has emerged as a potential therapeutic target for both cocaine and heroin/prescription opioid addiction (see also below). Centrally active KOP-r high-efficacy agonists are generally psychotomimetic with aversive properties. In rodent models of early relapse (reinstatement models), KOP-r antagonists prevented stress-induced reinstatement of cocaine-seeking behavior, although these antagonists did not block cocaine-induced reinstatement (37–39). KOP-r partial agonists can be hypothesized as a pharmacotherapeutic strategy for cocaine addiction and relapse (40). A partial agonist causes a submaximal response in comparison with full agonists, such as the endogenous KOP-r ligands, the dynorphins (41). A KOP-r partial agonist could therefore provide partial receptor tone in situations in which endogenous ligand is relatively deficient, but prevent overactivation of the KOP-r receptor system when the dynorphins are present at high levels. Thus, a selective KOP-r partial agonist could prevent stress-induced activation of KOP-r, contributing to relapse while also providing required homeostatic countermodulation of dopaminergic systems (25, 37, 42). Current clinically available ligands with KOP-r partial agonist effects (e.g., butorphanol or nalbuphine) are not selective, as they also display considerable MOP-r-mediated effects.

To date, no pharmacotherapeutic intervention in the treatment of cocaine addiction has been successfully developed. Current efforts in this regard target the endogenous opioid system, both with currently available compounds and potential new compounds with desired opioid receptor selectivity/activation profiles.

Heroin and prescription opioids

Abuse of illicit opiates continues to be a serious public health concern. According to the 2011 Monitoring the Future report, 1.2% of high school students in the USA reported lifetime use of heroin (43). Approximately 13% of high school seniors also reported nonmedical use of “other narcotic drugs,” such as the prescription opioids oxycodone and hydrocodone (44).

The main active metabolites of heroin and abused prescription opioids act primarily as agonists at MOP-r. Heroin (diacetylmorphine) enters the brain quickly and in high concentrations. Once in the brain, heroin is rapidly converted to the biologically active
metabolites morphine and monoacetylmorphine (45). These compounds bind MOP-\(r\) (e.g., on interneurons in the substantia nigra and ventral tegmental area) and relieve GABAergic inhibition of dopaminergic neurons (46). This results in release of dopamine into the projection fields (5, 24), where it interacts with pre- and postsynaptic dopaminergic receptors. A substantial portion of MOP-\(r\) agonists’ rewarding effects and addiction potential may thus be related to this downstream activation in dopaminergic fields. In animal studies modeling human abuse-related exposure to MOP-\(r\) agonists, several molecular regulatory changes were detected in components of the endogenous opioid receptor/neuropeptide and dopaminergic systems (47–50). These changes may be part of functional alterations postulated to underlie in part the chronic relapsing nature of heroin/prescription opioid addiction. Consistent with observations in human heroin abusers, we have shown that one inbred strain of rats escalated their self administration when given long-term (14-day), long-access (18-hour/day) availability of heroin (51), consistent with a genetic predisposition. Of potential translational importance, a recent article has suggested that high preexisting levels of Pdyn mRNA in the NAc (observed in a mouse strain) may protect against the acquisition of morphine-induced CPP (52). This suggests that high KOP-\(r\)/dynorphin tone may be protective at particular stages of addiction trajectory.

We have used siRNAs to demonstrate the critical role of the MOP-\(r\) in the substantia nigra and ventral tegmental area (where cell bodies for the nigrostriatal and mesolimbic dopaminergic systems are located) on heroin-induced rewarding effects (53). siRNA directed toward the mouse Oprm1 or GFP (as a control) were infused bilaterally into mouse midbrain dopaminergic areas. This siRNA infusion significantly reduced Oprm1 mRNA levels and MOP-\(r\)-binding density in these regions and also reduced the locomotor response to heroin and heroin-induced CPP (53). These data highlight the critical role of midbrain MOP-\(r\) in mediating behavioral and rewarding effects of heroin and also demonstrate the utility of region-specific targeted siRNAs in the neurobiological study of specific components of the reward system. Repeated preexposure to the widely abused prescription opioid oxycodone results in a sustained decrease in basal striatal dopamine dialysate levels in adult and adolescent mice (e.g., up to at least one week of withdrawal) (23). This is supportive of long-lasting adaptations in this crucial dopaminergic end point in the context of repeated exposure to and prolonged withdrawal from a prescription opioid.

**Stress systems in the neurobiology of addictions**

In humans, stress plays a major role in drug addiction and elevates drug craving. Stress-induced HPA activity predicted relapse to drug use and amounts of subsequent use, indicating that stress not only elicits craving, but also independently predicts relapse (54).

In the HPA axis, stress increases both corticotropin-releasing factor (CRF) and arginine-vasopressin (AVP) release into the pituitary portal circulation from terminals of hypothalamic paraventricular nucleus (PVN). Both CRF-R1 and AVP-V1b receptors are located on corticotropes in the anterior pituitary and drive the processing and release of ACTH and \(\beta\)-EP from the pro-opiomelanocortin (POMC) peptide, of particular interest for the field of addictive diseases (55, 56). Endogenous opioids are critical in the control of the HPA axis. Animal and human studies have demonstrated that \(\beta\)-EP and dynorphin exert tonic inhibition and stimulation of HPA activity acting on MOP-\(r\) and KOP-\(r\), respectively. In a rat study, either acute morphine or acute stress elevated HPA activity; in contrast, acute morphine blunted the HPA activation by stress, suggesting a counterregulatory role of opiates on the stress response (57). Both ACTH and cortisol levels are significantly disrupted in active heroin addicts; however, both basal activity and responsivity of the HPA axis are normalized in steady-state methadone-maintained patients (58). Rodent studies using pump infusion have confirmed that steady-state methadone does not alter HPA responsivity (31, 32, 59, 60). Morphine tolerance develops to the initial stimulatory effect, following long-term treatment (12, 61). Tolerance to MOP-\(r\) or KOP-\(r\) agonists, but no cross tolerance, is observed, suggesting the development of MOP-\(r\)- or KOP-\(r\)-specific tolerance (61).

Unlike the inhibitory effect of MOP-\(r\) agonists, cocaine stimulates HPA activity in humans. After a challenge dose of cocaine, ACTH response is significantly lower in cocaine-dependent men than in occasional cocaine users, indicating that attenuation of cocaine’s effects occurs after chronic cocaine use (62). Some human studies found that cocaine-addicted patients show higher basal plasma ACTH and cortisol levels at even up to three months of abstinence (for example, ref. 63); however, other studies have found no difference during abstinence in basal ACTH and cortisol levels (for example, refs. 18, 62). Notably, CRF or stress-induced HPA responses predict amounts of subsequent drug use in relapse, though the HPA hormonal increases are part of the nonspecific activation associated with psychological stress (54, 64). Furthermore, cocaine addicts are associated with HPA hyperresponsivity to glucocorticoid-negative feedback removal by metyrapone (18). In rats, cocaine rapidly elevates plasma ACTH and corticosterone levels, mediated by CRF and dopamine transmission (65–67). The HPA hormones in response to chronic cocaine show a significant attenuation compared with the acute effects, indicating tolerance of HPA activity to chronic cocaine (65). In early (1–2 day) cocaine withdrawal, there is a slight, but significant, increase in HPA hormones (68, 69). During protracted withdrawal from chronic escalating-dose (but not steady-dose) “binge” cocaine, enhanced AVP/V1b expression was associated with persistent elevations of HPA activity (56).

Increased CRF activity in the central nucleus of the amygdala (CeA) underlies the anxiogenic and stress-like consequences of withdrawal common to many drugs of abuse (68, 70). Activation of CeA CRF may play a role in reward deficits and dysphoria (71). CRF-R1 antagonists attenuate stress-induced reinstatement of cocaine or heroin seeking in rats (72). Administration of CRF to cocaine-addicted patients induced stress responses and subsequent cocaine craving (64).

Central AVP binds to two G protein–coupled receptor subtypes: V1a and V1b, both highly expressed in the rat extended amygdala. AVP-V1b receptors are expressed prominently in the amygdala, PVN, and hippocampus (73). Activation of V1b receptor pathways in the amygdala is an important step in the neurobiology of stress-related behaviors, including anxiogenic and depressive behaviors in rodents (74). We reported that amygdalar Atp gene expression levels were increased in acute heroin withdrawal, and a systemically active and highly selective AVP-V1b receptor antagonist dose-dependently blocked stress-induced reinstatement of heroin-seeking behavior (11, 75). Using genetically selected Sardinian alcohol-prefering rats, we further found that pharmacological blockade of AVP-V1b receptor attenuated alcohol drinking (76).
Together, these data suggest that the AVP-V1b system may be an important component of the neural circuitry contributing to drug withdrawal as well as drug-seeking and -taking behaviors. The opioid peptide β-EP (primarily a MOP-r agonist) is distributed in the hypothalamus and mesocorticolimbic regions, including the NAc. Because activation of MOP-r by β-EP is rewarding and modulates the NAc dopamine release (77), β-EP may be involved in the reinforcing effects of drugs of abuse (78). Compounds with MOP-r antagonist effects reduced the acquisition of cocaine self-administration behavior or CPP (79, 80), further raising the possibility that opioid neuropeptides play a functional role in the actions of cocaine at particular stages of addiction trajectory. Indeed, cocaine CPP is blunted in β-EP-deficient mice (81).

### The genetics of drug addictions

Genetic factors contribute to the vulnerability to developing drug addictions and to interindividual variability in the treatment efficacy for drug addiction (82). Polymorphisms in several genes, including genes encoding opioid receptors and ligands, were indicated in association with drug addiction (82–84). Here, we specifically discuss studies of the MOP-r gene (OPRM1), heroin addiction, and methadone maintenance treatment (MMT) for opioid addiction.

Two OPRM1 SNPs (17C>T and 118A>G) encode amino acid substitutions. The most studied OPRM1 variant is 118A>G (rs1799971), which causes the replacement of an asparagine residue by aspartic acid. This change results in removal of an N-glycosylation site in the extracellular domain, which in turn results in a higher affinity binding of β-EP than the prototype, altered receptor-binding site availability, and signaling efficacy as well as reduced mRNA levels (85–89). The 118G allele is most common in Asian populations (40%–50%), has moderate frequency in European populations (15%–30%), and has very low prevalence in African populations. Two mouse models of 118A>G show lower antinociceptive response and reward properties of morphine, reduction in the aversive effect of naloxone-precipitated morphine withdrawal, in a sex-dependent manner (90), reduction in N-linked glycosylation and protein stability (91), and greater dopamine response to an alcohol challenge (92).

A large number of association studies of SNP 118A>G have been reported and reviewed (93, 94). In two studies from this laboratory, the 118G variant was associated with alcoholism and heroin addiction in a sample of Swedish subjects with little genetic admixture (95, 96). The 118G allele has been associated with phenotypes including opioid dependence and other substance dependencies, alcoholism, attenuated HPA axis response to stress, and reduced clinical effects of opioid analgesics, although findings were not always consistent (86, 97–99). The mixed results may be explained in part by different haplotype patterns between populations. In a recent analysis (100), we showed that the 118G allele is positioned in part by different haplotype patterns between populations. Two mouse models of 118A>G show lower antinociceptive response and reward properties of morphine, reduction in the aversive effect of naloxone-precipitated morphine withdrawal, in a sex-dependent manner (90), reduction in N-linked glycosylation and protein stability (91), and greater dopamine response to an alcohol challenge (92).

### Pharmacogenetics of methadone maintenance treatment

One goal of pharmacogenetics is to develop individualized therapy in response to interindivdual variability in drug response. Methadone is a full MOP-r agonist and a weak NMDA receptor antagonist (Figure 1). Predicting individual sensitivity to methadone may help determine the most effective methadone dose. Methadone metabolism is attributed primarily to cytochrome P450 enzymes CYP3A4, CYP2B6, and CYP2D6. Methadone is a substrate of the ATP-binding cassette efflux transporter P-glycoprotein.

Several pharmacogenetics studies have aimed to identify genetic factors that modulate response to methadone maintenance (Table 1). We have identified three genes that may modulate response to methadone maintenance in a well-characterized sample from Israel. The ABCB1 synonymous SNP 1236C>T (rs1128503) was associated with higher methadone doses (>150 mg/d) (113). Subjects homozygous for the variant alleles of the functional CYP2B6 SNPs 785A>G (rs2279343) and 516G>T (rs3745274) (CYP2B6*6 allele) require lower doses than those of heterozygotes and noncarriers (114). An intronic SNP with unknown function (rs2239622) in the gene-encoding nerve growth factor (β polypeptide) (NGFB) that is involved in neural plasticity, memory, and behavior was shown to be associated with relatively low methadone doses (115).

<table>
<thead>
<tr>
<th>Gene</th>
<th>Definition</th>
<th>Selected ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABCB1</td>
<td>ATP-binding cassette, sub-family B (MDR/TAP), 1</td>
<td>113, 117</td>
</tr>
<tr>
<td>ARRB2</td>
<td>beta-arrestin 2</td>
<td>118</td>
</tr>
<tr>
<td>BDNF</td>
<td>brain-derived neurotrophic factor</td>
<td>119</td>
</tr>
<tr>
<td>CYP2B6</td>
<td>cytochrome P450, family 2, subfamily B, polypeptide 6</td>
<td>114, 117</td>
</tr>
<tr>
<td>CYP2D6</td>
<td>cytochrome P450, family 2, subfamily D, polypeptide 6</td>
<td>120</td>
</tr>
<tr>
<td>DRD2/ANKK1</td>
<td>dopamine D2 receptor/ankyrin repeat and kinase domain containing 1</td>
<td>117, 121, 122</td>
</tr>
<tr>
<td>GRM6</td>
<td>metabotropic glutamate receptor</td>
<td>123</td>
</tr>
<tr>
<td>KCNJ6</td>
<td>potassium inwardly rectifying channel</td>
<td>124</td>
</tr>
<tr>
<td>MYOCD</td>
<td>Myocardin</td>
<td>123</td>
</tr>
<tr>
<td>NGFB</td>
<td>nerve growth factor (beta polypeptide)</td>
<td>115</td>
</tr>
<tr>
<td>OPRM1</td>
<td>mu opioid receptor</td>
<td>117</td>
</tr>
</tbody>
</table>
Summary and conclusion

Drug-induced effects and neuroadaptations, specific genetic variants, and environmental factors all contribute to the development of specific addictive diseases. It is therefore essential to conduct laboratory-based studies and translational studies to determine the molecular neurobiology and genetic factors contributing to addictions, including the role of functional gene variants and epigenetic changes. The goal is to increase and optimize early interventions for the therapy of chronic addictive diseases that are extraordinarily costly in terms of human life, productivity, and cost to society (116).

Acknowledgments

The authors gratefully acknowledge funding from the NIH-National Institute on Drug Abuse (P60-DA05130 to M.J. Kreek and R21-DA031990 to B. Reed).

Address correspondence to: Mary Jeanne Kreek, Laboratory of the Biology of Addictive Diseases, The Rockefeller University, 1230 York Ave., Box 171, New York, New York 10065, USA. Phone: 212.327.8490; Fax: 212.327.8574; E-mail: kreek@rockefeller.edu.
Downloaded from http://www.jci.org on June 14, 2017. https://doi.org/10.1172/JCI60390


